# Experiences and Hopes Among Patients with Colorectal Carcinoma and Peritoneal Metastases Who Are Participating in an Early-Phase Clinical Trial

## TL;DR

Patients with colorectal cancer and peritoneal metastases felt hopeful about a new treatment called Radspherin® after surgery, despite challenges like pain and recovery.

## Contribution

The study reveals how patients experience and perceive a novel radionuclide treatment in an early-phase clinical trial.

## Key findings

- Participants felt hopeful and motivated by the chance to receive Radspherin®.
- Clear and supportive communication from doctors was highly valued by patients.
- None of the participants attributed side effects to Radspherin®.

## Abstract

This study explored how participants with peritoneal metastases from colorectal cancer experienced receiving an experimental treatment called Radspherin® two days after having completed cytoreductive surgery and heated intraperitoneal chemotherapy (CRS-HIPEC). Radspherin® is a novel radionuclide treatment injected directly into the abdominal cavity aiming to eradicate remaining cancer cells. Participants who took part in this early-phase clinical trial were interviewed about their experiences. They felt hopeful and motivated by the chance to receive Radspherin®, which they saw as a potential way to further improve their outcome. None attributed side effects to Radspherin®. They appreciated clear and supportive communication from their doctors but found the written mandatory study information overwhelming. Despite pain, fatigue, and long recovery times after CRS-HIPEC, they remained optimistic and focused on returning to a meaningful life. Hope, trust in healthcare providers, and good communication played important roles in patients’ decisions to join this clinical trial.

Background: Radspherin® is a novel α-emitting radiopharmaceutical administered intraperitoneally following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) for peritoneal metastases. It delivers short-range radiation aimed at eliminating residual microscopic disease. This qualitative study explored how participants with colorectal cancer experienced participating in an early-phase clinical trial involving CRS-HIPEC followed by Radspherin®. Materials and Methods: Semi-structured interviews were conducted with ten participants enrolled in a phase 1/2a trial involving CRS-HIPEC and intraperitoneal Radspherin®. The analysis was guided by a phenomenological and interpretive approach using reflexive thematic analysis. Results: Participants expressed a strong sense of motivation and hope tied specifically to receiving Radspherin®, which they perceived as an opportunity to improve their prognosis. Many also viewed participation as a contribution to future cancer research. None attributed complications or side effects to Radspherin®. Clear and supportive verbal communication from healthcare professionals was highly valued, while the written information was described as overwhelming. Despite fears of recurrence, most participants remained optimistic about regaining a meaningful life. While experiences with Radspherin® were largely positive, participants also described pain, fatigue, and prolonged recovery related to CRS-HIPEC, including ongoing functional and psychosocial challenges. Conclusions: Participants associated Radspherin® with hope and a therapeutic benefit but did not link it to their adverse events. Their willingness to participate in experimental treatment was shaped by trust in clinicians, clear communication, and a desire for extended survival. However, the burden of CRS-HIPEC-related side effects underscores the importance of tailored follow-up and support.